Biovica Q3: US launch progression - Redeye - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

Biovica Q3: US launch progression - Redeye

{newsItem.title}

With the recent CLIA lab certification (the US lab in San Diego), Biovica is moving into the next stage. The US sales team has already identified and established meetings with a large part of the NCI Designated Cancer Center network. The NCI target is, in our view, a sensible approach as these centres tend to be research oriented with the ambition to be leaders in laboratory and clinical research and well-funded. This network involves some 63 centres that meet patients (out of 71), and the NCI network covers most of the US, most located on the East and the West coast.

Länk till analysen i sin helhet: https://www.redeye.se/research/889940/biovica-q3-us-launch-progression?utm_source=finwire&utm_medium=RSS

Nyheter om Biovica

Läses av andra just nu

Om aktien Biovica

Senaste nytt